VBS Vectus Biosystems Limited
Healthcare · Biotechnology
· website
$0.11
52wk 0.07 – 0.46
Overall
81.4
Value
91.1
Growth
100.0
Health
98.9
Quality
100.0
Momentum
2.0
Dividend
—
Price
About Vectus Biosystems Limited
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address diseases driven by pathological tissue scarring. Its lead compound is VB0004, currently under phase Ib clinical human trial, which targets the prevention and reversal of fibrosis in the lungs, heart, and kidneys. The company was incorporated in 2005 and is based in Rosebery, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | -8.3% |
| 1 month | -40.5% |
| 3 months | -18.5% |
| 6 months | -26.7% |
| 1 year | 46.7% |
| 3 years | -70.3% |
Risk
| Volatility (1y ann.) | 177.0% |
| Beta vs ASX 200 | 0.90 |
| Sharpe (1y) | 0.95 |
| VaR 95% (1-day) | -12.5% |
| Max drawdown (1y) | -79.5% |
| Off 1-year high | -75.0% |
Technicals
| RSI(14) | 44 |
| vs 50DMA | -26.0% |
| vs 200DMA | -21.9% |
| Trend | Golden cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
91.1
Trailing P/E
100
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
71
Price / Sales
82
Growth
100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
98.9
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
98
Quality (Profitability & Cash Flow)
100.0
Return on equity
100
Return on assets
100
Operating margin
100
Net margin
100
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
2.0
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
9
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$6.84M
P/E (trailing)
3.67
P/E (forward)
—
EPS (trailing)
0.03
Dividend yield
—
Payout ratio
0.0%
Beta
0.33
EV / EBITDA
2.72
Price / Book
2.89
ROE
139.3%
Operating margin
76.4%
Net margin
56.3%
Total cash
$3.52M
Total debt
$546,665
Current ratio
3.79
Debt / Equity
0.24
Free cash flow
$1.44M
Avg volume
21,752
Latest annual results
(FY ending 30 Jun 2025)
- Revenue—
- Gross profit—
- Operating income—
- Net income—
- Diluted EPS-0.03
- Free cash flow—
- Net debt—